Table of Contents

Bleeding is the most common complication of any anticoagulant. For Eliquis (apixaban) users, the risk of a serious bleed is small in everyday life, but surgery increases that risk. Surgeons often need to control bleeding during an operation, and an anticoagulant makes this more difficult.

Each year, about 10% to 30% of patients on oral anticoagulants need to temporarily stop their medication for a planned procedure. Spinal or epidural anesthesia can be especially risky because blood can accumulate in the spinal canal and cause nerve damage.

This article explains how and when to stop Eliquis or apixaban before surgery and how to restart it afterward based on evidence from clinical trials and practice guidelines.

Key Takeaways

  • Minimal-risk procedures may require little or no interruption. Low to moderate risk typically requires holding apixaban for one day, while high-risk surgeries often require 2-4 days of interruption.
  • Patients with reduced creatinine clearance may need to stop apixaban earlier. Severe kidney impairment may contraindicate its use.
  • For low-risk surgery, Eliquis is typically restarted 24 hours after the procedure. For high-risk surgery, it’s usually restarted after 48-72 hours.

How long does the anticoagulant effect of Eliquis last?

Apixaban’s half-life of about 12 hours means that roughly half of the active drug is cleared every half-day. So, after stopping apixaban, its anticoagulant effect diminishes over the next couple of days:

    • Skipping two doses (24 hours) reduces the anticoagulant effect to about 25%
    • Skipping three doses (36 hours) reduces it to about 12%
    • Skipping four to five doses (48-60 hours) leaves only a small amount, especially if the kidneys are working normally

This is why guidelines often recommend skipping one or two days’ worth of doses, depending on procedure risk. Kidney disease slows the drug’s removal, so patients with a creatinine clearance below 50 mL/min may need to stop apixaban earlier.

Bleeding risk based on the type of procedure

When preparing for surgery, doctors categorize procedures based on bleeding risk. In general, procedures are grouped into:

Low bleeding risk surgeries/procedures

With low-risk procedures, the chance of major bleeding is about 0% to 2% within two days.

Category Examples Notes
Gastrointestinal procedures Colonoscopy, gastroscopy, sigmoidoscopy, endoscopic retrograde cholangiopancreatography (ERCP), capsule endoscopy, push enteroscopy, Barrett’s esophagus ablation This includes procedures that use a camera to look inside your digestive tract (stomach, intestines, or esophagus), sometimes with minor treatment
Cardiac procedures Pacemaker placement or battery change, defibrillator placement or battery change, AV node ablation, coronary angiography (radial approach) Includes heart-related procedures that are done through small incisions or blood vessels
Dental procedures Tooth extraction (up to 2 teeth), root canal (endodontic procedure) Common dental treatments involving removing or repairing teeth
Skin procedures Skin biopsy Removing a small piece of skin to test for disease
Eye procedures Phacoemulsification (cataract surgery) A common eye surgery to remove a cloudy lens (cataract) and replace it

High bleeding risk surgeries

With high-risk procedures, the chance of major bleeding increases to about 2% to 4% within two days.

Category Examples Notes
Neuraxial anesthesia procedures Neuraxial anesthesia/injection, epidural anesthesia/injection Injections or anesthesia given around the spine
Major brain or spine surgery Brain cancer resection, laminectomy, neuraxial tumor removal, intracranial bleed evacuation Surgery involving the brain or spinal cord, includes removing tumors or draining bleeding in the brain
Major chest (thoracic) surgery Lobectomy, pneumonectomy, esophagectomy Surgery in the chest, such as removing part or all of a lung or part of the esophagus (food pipe)
Major heart (cardiac) surgery Coronary artery bypass, valve repair/replacement Surgery on the heart, including bypassing blocked arteries or fixing/replacing heart valves
Major blood vessel (vascular) surgery Aortic aneurysm repair, aortobifemoral bypass, popliteal bypass, carotid endarterectomy Surgery on major blood vessels, such as repairing bulges (aneurysms) or clearing blocked arteries
Major abdominal or pelvic surgery Liver cancer surgery, pancreatic surgery, colorectal or stomach surgery, kidney or bladder cancer surgery, prostate surgery Surgery involving organs in the abdomen or pelvis (digestive system, urinary system, reproductive organs)
Major orthopedic surgery Hip or knee replacement, fracture repair, shoulder surgery, bone cutting (osteotomy) Surgery on bones and joints, often to replace or repair them
Other major cancer or reconstructive surgery Head and neck cancer surgery, reconstructive facial, abdominal, or limb surgery Large surgeries to remove cancer or rebuild body parts after injury or disease

How doctors assess your bleeding risk before surgery

Doctors also consider patient-specific risk factors. To assess your personal bleeding risk, they may use a tool called the HAS-BLED score.

Components of HAS-BLED include:

    • Hypertension – systolic blood pressure above 160 mm Hg
    • Abnormal renal – creatinine above 2.26 mg/dL or liver impairment, such as cirrhosis, or lab results indicating severe liver damage
    • Stroke History – previous history of stroke
    • Bleeding History – prior major bleeding or predisposition
    • Labile International Normalized Ratio (INR) – applies mainly to people on warfarin and describes difficulty keeping the INR within the therapeutic range
    • Elderly – age 65 years or older
    • Drugs/alcohol – refers to medications that increase bleeding risk, such as antiplatelet agents, or regular heavy alcohol use

Each factor adds one point to the total HAS-BLED score. After adding the points together, clinicians compare the total to risk categories.

    • A score of 0 or 1 indicates a low risk with about a 1% annual risk of major bleeding
    • A score of 2 suggests a moderate risk at roughly 2.1%
    • A score of 3 or more suggests a higher risk, around 3.4%

So, if your total score is greater than 3, you are considered to have a higher risk of bleeding.

How long before surgery should you stop Eliquis/apixaban?

The table below summarizes how long to hold Eliquis before surgery. Keep in mind that your provider may adjust these times based on your health status.

Procedure bleeding risk Kidney function Recommended time to stop Eliquis
Minimal or dental/skin procedures Normal or impaired No interruption or skip 1 dose the day of the procedure
Low to moderate risk (e.g., colonoscopy, laparoscopic surgery) CrCl 50 mL/min or higher Stop 1 day (24 hrs) before surgery
CrCl <50 mL/min Stop 2 days (48 hrs) before surgery
High risk (e.g., major orthopedic, abdominal, thoracic, cardiac) CrCl 50 mL/min or higher Stop 2 days (48 hrs) before surgery
CrCl <50 mL/min Stop 4 days (96 hrs) before surgery
Neuraxial anesthesia (spinal/epidural) Stop at least 3 days (72 hours) before the procedure

This is a general guide based on recommendations from organizations such as the American College of Cardiology and evidence from studies like the Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) study.

It is not a personalized treatment plan. Always follow the specific instructions provided by your surgeon and prescribing provider.

Urgent and emergency surgery while on Eliquis

If the surgery is urgent but can be delayed slightly, doctors will usually try to wait at least 12 to 24 hours after your last dose of Eliquis. This allows the medication level in your body to decrease naturally, which lowers the risk of bleeding. If time allows, they may also perform blood tests to estimate how much of the drug is still active in your system.

If surgery cannot be delayed and the bleeding risk is high, doctors may use a reversal agent such as andexanet alfa, which is specifically designed to reverse the effects of Eliquis.

In the ANNEXA-4 trial, patients showed a rapid reduction in anti-factor Xa activity within 4 hours after receiving andexanet alfa, and 82% of patients achieved good or excellent control of bleeding. Additional smaller studies in patients with serious bleeding in the brain or gastrointestinal tract showed that 48% to 90% of patients achieved good or excellent bleeding control after receiving the reversal agent.

In a 2022 study, about 79% of patients achieved good or excellent bleeding control within 24 hours after receiving andexanet alfa around the time of a procedure.

How soon can you restart Eliquis after surgery?

According to the 2025 guidelines:

  • After high bleeding risk surgery:
      • Restart your regular (full) Eliquis dose after 48-72 hours (2-3 days)
  • If bleeding risk is still high:
      • You may start with a lower dose (Eliquis 2.5 mg twice daily) first
      • Then switch back to your full dose when it’s safe
  • If you normally take a low (preventive) dose of Eliquis:
      • You may restart it sooner, about 12-24 hours after surgery, if there’s no increased bleeding risk
  • If you cannot take oral meds after surgery:
      • A different blood thinner (injection) may be used temporarily until you can take Eliquis again

Always consult your surgeon and hematologist for individualized plans.

Talking to your healthcare team

Planning a surgical procedure while on Eliquis requires teamwork between you and your healthcare providers.

Start by letting your prescribing physician know about your upcoming surgery or procedure as soon as it is scheduled. Provide the exact date and time of your procedure and discuss your personal risk factors. Ask your clinician to give you written instructions that specify which doses to skip. Bring these instructions to your pre-operative appointment and share them with your surgeon and anesthesiologist.

During the discussion, cover the following points:

  • Procedure type and bleeding risk. Is your procedure considered minimal, low, moderate, or high risk?
  • Kidney function and other health conditions. Recent lab results can help decide how long to stop apixaban.
  • Current medications. Provide a list of all prescription drugs, over-the-counter medicines, and herbal supplements.
  • Recent bleeding history or falls. A history of gastrointestinal bleeding, nosebleeds, or falls may influence timing.
  • Who will manage bridging or prophylactic anticoagulation? In most cases, bridging is not needed. But if your doctor decides to use LMWH after surgery, confirm who will prescribe and monitor it.

If you have any doubt about instructions or your plan changes, contact your prescribing clinician right away. The plan may need adjustment if your surgery is delayed, your kidney function changes, or you start taking a new medication.

Eliquis coupons and discounts

Starts from $157

Have a prescription?

Choose Pharma Giant for affordable medications and take control of your health with reliable, cost-effective options today!

SAVE 10% with coupon code:

Bottom line

Stopping Eliquis before surgery requires careful, individualized planning. For most procedures, it is stopped 1-2 days before and restarted 24-72 hours after, depending on bleeding risk. Special situations, such as kidney problems or spinal procedures, may require longer interruption.

Evidence shows this approach keeps both bleeding and clot risks low, and bridging is usually not needed. In urgent cases, reversal agents may be used. Always follow your doctor’s instructions, inform them of all medications, and report any unusual symptoms to ensure safe management around surgery.

Frequently Asked Questions

If you forget to take a scheduled dose of apixaban, take it as soon as you remember on the same day and then resume your regular twice-daily schedule. Do not take two doses at once to make up for the missed tablet. If you are unsure when to take your next dose, contact your healthcare provider.

Apixaban has few dietary restrictions, but certain foods and herbal products can raise or lower drug levels. Grapefruit, grapefruit juice, pomelos, limes, marmalades, garlic, ginger, chamomile tea, green tea, and turmeric can slow apixaban’s breakdown, and herbs such as ginkgo biloba, vitamin E, and fish oil may increase bleeding risk. Review all supplements with your doctor.

Heavy alcohol use should be avoided because alcohol itself thins the blood and can increase bleeding.

Apixaban is rapidly absorbed and reaches peak effect one to two hours after a dose. When you restart the medication after surgery, it begins to thin your blood within a few hours, so follow your provider’s timing instructions closely.

Yes. A specific antidote called andexanet alfa acts as a decoy to neutralize apixaban’s anticoagulant effect. Because apixaban’s effect lasts for at least 24 hours after the last dose, doctors may also use prothrombin complex concentrate or activated charcoal to reduce bleeding, but these options have limited supporting evidence.

Unlike warfarin, apixaban has predictable pharmacokinetics and does not require routine laboratory monitoring. Laboratory tests to measure anti-factor Xa levels may be useful in specific situations, such as suspected drug interactions, extreme body weight, or kidney failure, but routine testing is not recommended because there is no evidence that dose adjustments based on drug level improve outcomes.

Yes. Inform all members of your healthcare team, including dentists, dental surgeons, pharmacists, and other practitioners, that you take apixaban. Minor dental procedures such as tooth extraction or cataract surgery can often be performed without stopping the medication, but always follow the specific instructions given by your provider.

Avoid combining apixaban with strong P-glycoprotein and CYP3A4 inducers such as rifampin, carbamazepine, phenytoin, and St John’s wort because they decrease apixaban levels and could increase your risk of stroke. Drugs that affect hemostasis, including aspirin, clopidogrel, other antiplatelet agents, fibrinolytics, heparin, and chronic NSAIDs, raise bleeding risk when taken with apixaban. Always consult your doctor before starting or stopping any medication.

Related Articles

Sources

Tran, H. A., Merriman, E., Baker, R., Curnow, J., Young, L., Tan, C. W., McRae, S., & Chunilal, S. D. (2025). 2025 Guidelines for direct oral anticoagulants: a practical guidance on the prescription, laboratory testing, peri?operative and bleeding management. Internal Medicine Journal, 55(7), 1174–1183. https://doi.org/10.1111/imj.70103

Gutierrez, J. J. P., & Rocuts, K. R. (2023, January 23). Perioperative anticoagulation management. StatPearls – NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK557590/

Perioperative Management of DOACs: Key Points – American College of Cardiology. (2024, August 15). American College of Cardiology. https://www.acc.org/latest-in-cardiology/ten-points-to-remember/2024/08/15/15/36/perioperative-management-of

Connolly, S. J., Crowther, M., Eikelboom, J. W., Gibson, C. M., Curnutte, J. T., Lawrence, J. H., Yue, P., Bronson, M. D., Lu, G., Conley, P. B., Verhamme, P., Schmidt, J., Middeldorp, S., Cohen, A. T., Beyer-Westendorf, J., Albaladejo, P., Lopez-Sendon, J., Demchuk, A. M., Pallin, D. J., . . . Milling, T. J. (2019). Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors. New England Journal of Medicine, 380(14), 1326–1335. https://doi.org/10.1056/nejmoa1814051

Bradshaw, P. G., Keegan, S. P., Droege, M. E., Dykes, N. J. H., Ernst, N. E., Foertsch, M. J., Makley, A. T., Mueller, E. W., Philpott, C. D., Srinivasan, V., Winter, J. B., Goodman, M. D., & Droege, C. A. (2022). Reversal of apixaban and rivaroxaban with andexanet alfa prior to invasive or surgical procedures. Pharmacotherapy the Journal of Human Pharmacology and Drug Therapy, 42(10), 780–791. https://doi.org/10.1002/phar.2727

Douketis, J. D., & Spyropoulos, A. C. (2024). Perioperative management of patients taking direct oral anticoagulants. JAMA, 332(10), 825. https://doi.org/10.1001/jama.2024.12708

Tafur, A. J., Clark, N. P., Spyropoulos, A. C., Li, N., Kaplovitch, E., MacDougall, K., Schulman, S., Caprini, J. A., & Douketis, J. (2020). Predictors of bleeding in the Perioperative Anticoagulant Use for surgery Evaluation study. Journal of the American Heart Association, 9(19), e017316. https://doi.org/10.1161/jaha.120.017316

Moster, M., & Bolliger, D. (2022). Perioperative Guidelines on Antiplatelet and Anticoagulant Agents: 2022 update. Current Anesthesiology Reports, 12(2), 286–296. https://doi.org/10.1007/s40140-021-00511-z

Douketis, J. D., Spyropoulos, A. C., Duncan, J., Carrier, M., Gal, G. L., Tafur, A. J., Vanassche, T., Verhamme, P., Shivakumar, S., Gross, P. L., Lee, A. Y. Y., Yeo, E., Solymoss, S., Kassis, J., Templier, G. L., Kowalski, S., Blostein, M., Shah, V., MacKay, E., . . . Schulman, S. (2019). Perioperative management of patients with atrial fibrillation receiving a direct oral anticoagulant. JAMA Internal Medicine, 179(11), 1469. https://doi.org/10.1001/jamainternmed.2019.2431